Bone Neoplasms Epidemiology Forecast

Bone-Neoplasms Insights and Trends

• Bone tumors are a heterogeneous group of neoplasms that arise either within the bone (primary tumors) or spread to the bone from other sites (secondary or metastatic tumors). Primary bone tumors are classified as benign or malignant, with each type exhibiting distinct biological behavior, clinical presentation, and treatment outcomes. Among malignant primary bone tumors, osteosarcoma is the most common, particularly affecting adolescents and young adults during periods of rapid growth
• According to DelveInsight’s analysis, In the US, primary bone and joint cancers remain uncommon, with an estimated 4,110 new cases, representing only 0.2% of all new cancer diagnoses. 
• The diagnosis of bone neoplasms involves a combination of clinical evaluation, imaging studies, and histopathological confirmation. Patients typically present with persistent localized bone pain, swelling, or a palpable mass, although symptoms may be nonspecific and contribute to delayed diagnosis. Initial assessment generally includes plain radiography, followed by advanced imaging modalities such as magnetic resonance imaging (MRI) and computed tomography (CT) to determine tumor location, extent, and involvement of surrounding tissues. Bone scans or positron emission tomography (PET) may be used to assess metastatic spread. 
• Definitive diagnosis requires a biopsy with histopathological examination, often supplemented by immunohistochemistry and molecular testing to accurately classify the tumor subtype and guide treatment planning. Early and accurate diagnosis is critical for optimizing therapeutic outcomes and improving survival in patients with malignant bone tumors.

DelveInsight’s “Bone-Neoplasms Epidemiology, Forecast – 2036” report delivers an in depth understanding of bone-neoplasms, historical and forecasted epidemiology in the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.

Geography Covered

North America: The United States

Europe: Germany, France, Italy, and Spain and the United Kingdom

Asia-Pacific: Japan

Bone-Neoplasms Understanding

Bone-Neoplasms Overview and Diagnosis

Bone tumors comprise a diverse group of neoplasms that may arise directly from bone (primary tumors) or result from the spread of cancer from other organs (secondary/metastatic tumors). Primary bone tumors can be benign or malignant, with each type differing in clinical behavior and treatment approach. The major malignant primary bone tumors include osteosarcoma, the most common form, which primarily affects adolescents and young adults and typically develops in long bones; Ewing’s sarcoma, an aggressive tumor seen mainly in children and young adults; and chondrosarcoma, a cartilage-forming malignancy that occurs more frequently in adults. The occurrence of bone tumors is influenced by factors such as age, sex, geographic variation, and genetic susceptibility, with osteosarcoma showing a characteristic bimodal age distribution during adolescence and later adulthood.

The diagnostic workup for bone neoplasms begins with clinical evaluation incorporating patient age, symptom onset, lesion location, and radiographic appearance — with conventional X-ray findings enabling correct diagnosis in over 80% of patients. MRI serves as the gold-standard imaging modality, superior in detecting bone marrow involvement, intramedullary extension, and invasion of adjacent joints, muscle compartments, and neurovascular bundles. CT scans further evaluate soft-tissue spread and distant organ metastases, while PET scans provide a whole-body metabolic map to detect systemic disease. Biopsy constitutes the final diagnostic step, completing tumor staging and histological grading, and must be performed after all imaging, in close consultation with the operating surgeon, as the biopsy track must be excised with the tumor.

Further details related to country-based variations are provided in the report…

Bone-Neoplasms Epidemiology

Key Findings from Bone-Neoplasms Epidemiological Analysis and Forecast

• In the US, primary bone and joint cancers remain uncommon, with an estimated 4,110 new cases, representing only 0.2% of all new cancer diagnoses. Osteosarcoma is the most common subtype among children and adolescents, whereas chondrosarcoma predominates in adults.
• In the 7MM, there were approximately 1,200 and 900 cases of osteosarcoma in male and female respectively. The higher incidence in males is primarily attributed to differences in adolescent skeletal growth patterns, with males generally experiencing a longer and more pronounced pubertal growth spurt, which has been associated with an increased risk of osteosarcoma development during periods of rapid bone growth.
• Malignant neoplasm of bone and articular cartilage (MNBAC) exhibits a bimodal age distribution, peaking in adolescents (10–14 years) and older adults (>65 years), and is characterized by nonspecific early symptoms, local aggressiveness, and a high risk of pulmonary metastasis.
• A consistent male predominance has been observed in osteosarcoma, with a male-to-female ratio ranging from approximately 1.3:1 to 1.5:1. The lungs are the predominant metastatic site, accounting for roughly 90% of distant spread, and pulmonary metastases remain the leading cause of osteosarcoma-related mortality.

Further details related to country-based variations are provided in the report…

Scope of the Report

• The report covers a segment of key events, an executive summary, a descriptive overview of bone-neoplasms, explaining its causes, signs and symptoms, and pathogenesis.
• Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of the diagnosis rate, and disease progression.

Report Insights

Bone-Neoplasms Patient Population Forecast

Report Key Strengths

• Epidemiology‑based (Epi‑based) Bottom‑up Forecasting
• Artificial Intelligence (AI)-Enabled Market Research Report 
• 11-Year Forecast 

FAQs

• What are the disease risks, burdens, and unmet needs of bone-neoplasms? 
• What will be the growth opportunities across the 7MM concerning the patient population with bone-neoplasms?
• What is the bone-neoplasms incidence in the US, EU4 (Germany, France, Italy, and Spain), the UK, and Japan?
• What is the historical and forecasted bone-neoplasms patient pool in the US, EU4 (Germany, France, Italy, and Spain), the UK, and Japan?

Reasons to Buy

• Insights on bone-neoplasms burden and disease incidence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
• To understand key opinion leaders’ perspectives around the diagnostic challenges to overcome barriers in the future.
• Detailed insights on various factors hampering disease diagnosis and other existing diagnostic challenges.
• Clear methodology, validated assumptions, and data-driven rationale to assess the bone-neoplasms epidemiology analysis and patient population trends.